Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study

BACKGROUND: In RADIANT-4, everolimus showed an improvement of 7.1 months in median progression-free survival (PFS) vs placebo among patients with advanced, well-differentiated, nonfunctional neuroendocrine tumors (NETs) of gastrointestinal (GI) or lung origin. The present analysis focuses on the eff...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Onco Targets Ther
Autori principali: Yao, James C, Oh, Do-Youn, Qian, Jiaming, Park, Young Suk, Herbst, Fabian, Ridolfi, Antonia, Izquierdo, Miguel, Ito, Tetsuhide, Jia, Liqun, Komoto, Izumi, Sriuranpong, Virote, Shimada, Yasuhiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6400121/
https://ncbi.nlm.nih.gov/pubmed/30881026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182259
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi